Modification makes immunotherapy for blood cancer even more effective
Peer-Reviewed Publication
Updates every hour. Last Updated: 11-Jul-2025 04:11 ET (11-Jul-2025 08:11 GMT/UTC)
New research from Memorial Sloan Kettering Cancer Center (MSK) uncovers new details of the immune response against leptomeningeal metastasis; develops a grading system to assess the risk of developing thrombocytopenia after CAR T cell therapy; outlines a method for scientists to estimate metabolic characteristics from challenging clinical samples; and probes CRISPR’s anti-viral capabilities.
The demand for the widely used cancer drug Taxol is increasing, but it’s difficult and expensive to produce because it hasn’t been possible to do it biosynthetically. Until now, that is. Researchers from the University of Copenhagen have cracked the last part of a code that science has struggled with for 30 years. The breakthrough could halve the price of the drug and make production far more sustainable.
Deep-penetration light-triggered pyroptosis based on nanomedicine for tumor precision therapy still remains challenging. Towards this goal, Scientist in China reported a supramolecular engineering strategy to construct Pt(IV)-coordinated supra-(carbon dots) with NIR-activated photocatalytic capacity to trigger tumor pyroptosis, thereby evoking anti-tumor immune responses to suppress distant tumor and prevent cancer metastasis. The finding will open new avenues for precision phototherapy in future clinical oncology by supramolecular-mediated nanomedicine with deep-penetration light triggered pyroptosis.
If you have cancer, you expect to see an oncologist, but if you have heart failure you may or may not see a cardiologist. According to research published in the European Heart Journal, only around three out of five heart failure patients see a cardiologist at least once a year. The study also shows that patients who do see a cardiologist once a year are around 24% less likely to die in the following year.
A research team from Sun Yat-sen University Sixth Affiliated Hospital has made a groundbreaking discovery in colorectal cancer (CRC) research, identifying a long noncoding RNA (lncRNA) named ESSENCE (EGF Signal Sensing CAD's Effect; ENST00000415336) as a critical regulator of tumor progression. The study reveals that ESSENCE stabilizes a key metabolic enzyme, CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase), to promote cancer growth and suppress ferroptosis. The findings also propose a novel combination therapy targeting ESSENCE-high tumors, offering new hope for precision treatment.